Environmental industries?

Gabor and Andras are both co founders of Modern Meadow and are working together along with Organovo patent contributor Karoly Jakab.
They left on good terms and they haven't cashed in their stock holdings(+10%), so not sure of the conspiracy theory you are trying to make?

Guten tag mein freund

Nice to have you here, the world is getting smaller by the day around here.
Please keep us informed on the European front.
Lots of good things will be coming from your part of the dirt that will affect Organovo's business model.

I say never deny a man what he likes to do, so post those charts whenever you feel the need.
I will appreciate the data hotrod, always something to learn.

...and who ever bought them might be a genius

Here's an interesting little bone:

Subsequent Events
On October 8, 2013, Organovo, Inc. signed a Letter of Intent with ARE — SD Region No. 25, LLC, the current landlord, proposing to enter into a lease amendment to expand the leasable premises at its current location, 6275 Nancy Ridge Drive, San Diego, CA.

Earnings have been released. 10Q is not what we hoped for but expected.

AWESOME

I'm glad I have come to the same conclusions as you and the fine folks your associated with.
This might be a little sappy for a stock message board, but things like this renews my faith in humans.

Support humanity with any resource available to you: OneOrgan Network is a fine example of this.

Good morning to you sir, hope its a lovely day in your neighborhood. Wouldn't hurt to update the board on what Methuselah is doing, if you have the time. Thanks, your never wavering confidence is this company is high on my list of pros for holding long term.

Good question this morning uk. I see your point and feel that pharma is probably getting the scientific evidence ready because they know that they will be turning in data from using Organovo's products, and they will have to explain this new platform. Hope they do a good job of it.

I also think your on to the right thought with the EU connection, its good to have world wide patents and a more liberal system to get things going as the proving ground of the first test model. It's also good to have customers who operate outside of the US.
Lot of good ideas kicked around here, hope your closer to a comfortable answer.

'bout time for the 5point restraint, huh hotrod?

After today I'm free to be a buyer if she gaps up or, hopefully for me, a signature 5% retrace tomorrow around 7:30. Either way, I agree with dshade +9

The FDA is about science and data. The more predictive the science the better the data.
It won't be ONVO that has to prove the method, it will be pharma's job to show them the benefits of this platform. Keith mentions this in the roadshow from Sept, and even said it might possibly turn into the FDA 'requiring this method' on all drug screening work in the future. That would be sweet.

Great link anarmyofme, was wondering when someone would expand on the PR. Should see more coming from mainstream sources, this topic needs more exposure.

Never a dull moment, love this stock!

EOD was a good time to load up. Lots of buyers in the last half hour and looks good for tomorrow. Can't see this profit taking a smart move past today.

Welcome to the ONVO board sir!
Does your presence here indicate you have taken an interest in our fine company? ;)
Looking forward to your well seasoned wisdom, lots of good folks here.

Great attempt at valuation RR, its why I leave it to the pros. Zacks is the only analyst that I've seen make an attempt, and they report plates going for 8-10K with an a estimate of 20-30mil per drug with up front/milestone/royalty revenue.

My attempt is assuming a 1B drug is a home run for pharma, and ONVO was part of the research on that drug, then with a 7% royalty on the drugs revenue I see a +70mil accumulated payday. That's per drug/company. Take that times your list(small IMO) and that's all I need to know for now.

End of 2Q is 9/30. Last release was 45 days after, so we are figuring 11/15. Don't think Earnings will show much on this Q, as still no revenues to speak of. Looking for insights into the new collaborations is what I'm hoping to discern. Best place is the company: http://ir.organovo.com/investors/sec-filings
Hope that helps.

I have 35% of my portfolio in ONVO at 4.06 average, and use 20% for trading. I have made 5 trades since the uplisting and up 14K. Just started my 6th trade at 6.80 and figure to hold until near 8.
That's my fun.

I agree, the structual integrity of the constructs were prohibitive with the past time frames(5day), and I think everyone is now understanding the importance of the 40 day foundation to pharma. What I find cool is that not only will pharma pay for the assays for testing, they will also speed up NEW drug discoveries that will bring a more quality drug to market faster. Organovo will have structured royalties on each new drug brought to market. Huge revenue stream if done correctly.

It seems that this will become the norm for all the skeptics of this company. Developmental progress of the products has changed a few minds in my circle, and future probabilities are outweighing any negative arguments. +90% sp change in the last 6 months helps.

Welcome to the board sir. Usually pretty friendly around here with the exchange of facts and ideas. Lots of folks here know this story well, so please feel free to ask anything you need to know, and we'll let the mods handle the rambunctious ones.

I will be all over this company if and when they take it public, not for the food but for the leather markets.
Think Lazyboy, Spaulding and Nike and you start to formulate the markets. It will track the same short/long term products as ONVO's.

Gabor and his son Andras Forgacs are visionaries and their names will be synonymous with the likes of Edison.

P.S. Karoly Jakab is Gabor's mini me, I suspect we will see his name in print as well.

Preferable? 2B is the buyout number being kicked around, $42 share. To me that's where we will be once assays are in full swing and royalties start coming in, 2-3 years my est. This does not take into account the surgical ready tissues now being developed and certainly not full tissues for transplant. Real money with those products. I will scream bloody murder when the first buyout attempt is made. JMO.

Last 3 days at 9:30. Is this the funds buying?

I think Keith knows the importance of this media. The guy makes me smile a lot.

Did you know that they were in pre-clinical trails with their surgical grade tissues?
That one was news to me, but I don't have the scientific resources.
Good to see developmental progress with that product though.

Very nice 3DP, didn't take long at all.
I like that this company doesn't mess around with getting legitimate questions answered. One of the cool surprises for me.

Thanks for including my question on patents, I was wondering if they were protecting any child patent derived from the original, looks like all is good!

The management team had a 60 day lock out period (except for the CTO's 75K) after the offering, otherwise like da55id said, the shares hit the street that day.

Looking forward to tonight's forum, should have lots of new info for us!
Your interview is timely also:)

Keith Murphy will be speaking on the Crawford Family Forum Tuesday Oct. 22 at 7:00pm PST.

http://www.scpr.org/events/2013/10/22/1212/next-3d-bioprinting/

I am really excited about this forum as Andrew Hassel of Autodesk's Bio/Nano Programmable Matter group is also on the agenda. Fascinating speaker on next generation technologies.

If I'm not to late, an update on the patents from the UK(GB2478801 and GB2489081) on vascular tubes would be another question of mine. Thanks

When will your article be published? Will it be on your web site?

I would like to know more about the raw material provider ZenBio.

I haven't been trading for that long, but I've never seen a company give so much detail before to explain their trading plans. Way cool! Makes me feel good to know that Dr. Presnell is sticking around with a house purchase!

This is Sharon Presnell's second disposal of 75K of securities under the trading plan from 6/2013. There is a previous 4 filed on 8/14. The 10K from March is where you find executive compensation information, but I am unable to verify the original 224,064 shares she reports on the 4. Anyone able to find the math, let me know.
Hope this helps.

Sounds like a productive conference, thanks for the update chaos!

I found it surprising too. Your company is so large that IR doesn't know who they do business with? I asked them to keep me informed if and when Organovo hits their screen.

Welcome to the family

FYI, I wrote to the IR of Roche and this was their response to my inquiry.

Thanks for your email to the Roche Investor Relations North America email inbox.

We were made aware of this vendor relationship from another inquirer, but we do not really know much about it. As you can imagine, we have hundreds if not thousands of vendors and we do not know the details behind each contract.

With sincere regards,

Thomas Kudsk Larsen
Head of Investor Relations North America
Vice President

But the good news is it could be them, or Pfizer or United Therapeutics or Knight Cancer Institute or the Michael J Fox Foundation or a new collaboration not yet announced. IMO, today is a good day to take a position.

I speck after that ass kicking he received by the community over there, I doubt he has the balls to write another hit piece on Organovo. If he does, I'll offer my boot again to his non-fact based drivel. Pissed me off for sure.

... and no negative catalyst in the near future.

RR, great article! I can see more sophisticated investors coming from this challenge. How did you find this? Are you associated with the Oregon Health system?